Agilent Technologies Crecimiento futuro
Future controles de criterios 2/6
Se prevé un crecimiento anual de los beneficios y los ingresos de Agilent Technologies de 13.3% y 6.4% por año respectivamente. Se prevé que el BPA crezca en un 13.5% al año. Se espera que la rentabilidad financiera sea de 21.7% en 3 años.
Información clave
13.3%
Tasa de crecimiento de los beneficios
13.55%
Tasa de crecimiento del BPA
| Crecimiento de los beneficios de Life Sciences | 16.9% |
| Tasa de crecimiento de los ingresos | 6.4% |
| Rentabilidad financiera futura | 21.74% |
| Cobertura de analistas | Good |
| Última actualización | 17 Apr 2026 |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
Actualización del análisis • Apr 25
A: New Diagnostic Approvals And Buybacks Will Support Long Term Upside
Analysts have trimmed their price target on Agilent Technologies by about $1 to $160.69, reflecting slightly adjusted views on fair value, discount rate, revenue growth, profit margin, and future P/E assumptions. What's in the News The Supreme Court of the United States denied Agilent Technologies' petition related to two CRISPR guide RNA patents, leaving in place prior rulings that found all claims of the patents unpatentable.Actualización del análisis • Apr 09
A: New Diagnostic Expansion And Guidance Will Support Long Term Upside
Analysts have slightly reduced their price target on Agilent Technologies by about $1, citing updated assumptions for fair value, discount rate, revenue growth, profit margin, and future P/E. They indicate that the overall outlook remains largely intact.Actualización del análisis • Mar 26
A: New Diagnostic Approval Will Drive Upside For Long Term Outlook
Analysts have made a slight trim to their price target for Agilent Technologies to about $163.19 from around $163.29, citing updated assumptions for revenue growth, profit margins and a somewhat lower future P/E multiple. What's in the News The FDA approved Agilent's PD-L1 IHC 22C3 pharmDx, Code SK006, as a companion diagnostic to help identify first line patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma who may be eligible for treatment with KEYTRUDA, adding a seventh companion diagnostic indication for this assay (Key Developments).Actualización del análisis • Mar 11
A: New Diagnostic Approvals And Digital Pathology Expansion Will Drive Upside
Analysts have trimmed their price target on Agilent Technologies to about $163 from roughly $170, citing modest tweaks to their models, including slightly adjusted revenue growth, discount rate, profit margin, and future P/E assumptions. What's in the News Agilent issued earnings guidance for fiscal Q2 2026, with revenue expected in the range of $1.79b to $1.82b, framed as approximately 7% to 9% reported growth and 4% to 5.5% core growth (company guidance).Seeking Alpha • Mar 10
Why Agilent Technologies Just Paid $950 Million For Biocare Medical
Summary Agilent Technologies (A) acquires Biocare Medical for $950M to expand into high-growth pathology and cancer diagnostics, enhancing recurring consumables revenue streams. A trades below historical valuation multiples, presenting an opportunity if management executes on diagnostics expansion and leverages its global distribution to scale Biocare’s offerings. 1Q26 results showed 7% reported revenue growth to $1.80B, with non-GAAP EPS up 4% year-over-year, and management raised FY26 guidance for both revenue and EPS. The Biocare deal accelerates Agilent’s shift toward higher-margin, recurring revenue, with management expecting positive EPS contribution within 12 months post-close. Read the full article on Seeking AlphaActualización del análisis • Feb 25
A: New Diagnostic Approvals Will Support Measured Upside Ahead
Analysts reaffirm a price target of $169.67 for Agilent Technologies, citing largely unchanged assumptions for the discount rate, revenue growth, profit margin, and future P/E. These factors together keep their valuation framework intact.Actualización del análisis • Feb 10
A: New Digital Pathology And Board Declassification Will Support Measured Upside Ahead
Analysts have modestly trimmed their price target on Agilent Technologies to reflect slightly higher discount rate assumptions and a lower future P/E, while still incorporating steady revenue growth and a marginally stronger profit margin outlook. What's in the News Agilent plans to ask shareholders at the March 18, 2026 AGM to approve an amendment to its Third Amended and Restated Certificate of Incorporation that would declassify the board of directors over three years, shifting toward annual director elections (Key Developments).Actualización del análisis • Jan 26
A: New Digital Pathology And Buybacks Will Support Measured Upside Ahead
Analysts have nudged their price target on Agilent Technologies slightly higher to about US$170, citing updated assumptions around fair value, discount rates, revenue growth, profit margins and future P/E, which collectively support a modest upward revision. What's in the News Agilent launched the S540 MD Slide Scanner System for whole slide imaging in key European markets, adding a high throughput digital pathology scanner with capacity for 540 slides and AI assisted tissue detection to its portfolio (Product Related Announcements).Actualización del análisis • Jan 11
A: New CFO And Capital Returns Will Support Measured Upside Ahead
Analysts have nudged their price target for Agilent Technologies slightly lower to US$168.59 from US$169.44, citing small adjustments to their fair value estimate, discount rate, revenue growth outlook, profit margin assumptions, and future P/E expectations. What's in the News Agilent outlined fiscal first quarter 2026 revenue guidance of US$1.79b to US$1.82b and fiscal 2026 revenue guidance of US$7.3b to US$7.4b, with both ranges expressed in reported and core terms (Corporate guidance).Artículo de análisis • Dec 18
Agilent Technologies (NYSE:A) Is Increasing Its Dividend To $0.255
Agilent Technologies, Inc. ( NYSE:A ) has announced that it will be increasing its dividend from last year's comparable...Actualización del análisis • Dec 15
A: New Leadership And Compliance Software Will Support Measured Upside Ahead
Analysts have nudged their average price target on Agilent Technologies higher by about $2 to roughly $169.44, citing slightly faster expected revenue growth and a modestly lower discount rate that more than offset a small downward revision to long term profit margins. What's in the News Launched 21 CFR Part 11 compliant software for the xCELLigence RTCA eSight system, enabling secure deployment in GMP manufacturing and QC labs with features such as secure logins, e-signatures, and full audit trails (Key Developments).Actualización del análisis • Nov 30
A: New Diagnostic Solutions And Leadership Will Shape Measured Prospects Ahead
Analysts have raised their price target for Agilent Technologies from $152.33 to $167.57, citing modestly higher expectations for revenue growth and valuation metrics as the primary reasons for the change. What's in the News Agilent Technologies provided earnings guidance for fiscal Q1 2026, expecting revenue in the range of $1.79 billion to $1.82 billion, up 6% to 8% reported and 4% to 6% core.Artículo de análisis • Nov 27
Agilent Technologies, Inc. (NYSE:A) Analysts Are Pretty Bullish On The Stock After Recent Results
It's been a good week for Agilent Technologies, Inc. ( NYSE:A ) shareholders, because the company has just released its...Actualización del análisis • Nov 16
A: Product Launches And Diagnostic Approval Will Support Balanced Outlook
Narrative Update: Agilent Technologies Analyst Price Target Revision Analysts have raised their price target for Agilent Technologies from $149.90 to $152.33. This change reflects modest upward revisions in projected revenue growth and a slightly higher expected future valuation multiple.Actualización del análisis • Nov 01
A: Global Healthcare Trends And New Diagnostic Solutions Will Shape Future Performance
Analysts have slightly raised their price target for Agilent Technologies from $148.57 to $149.90, citing stable fundamentals and a modest valuation adjustment. What's in the News Adam S.Actualización del análisis • Oct 18
Global Healthcare Demand And PFAS Testing Will Drive Analytical Progress
Analysts have raised their price target for Agilent Technologies from $140.97 to $148.57, citing improved revenue growth prospects and higher expected profit margins as key drivers behind the upward revision. What's in the News Announced launch of Insight Series Alarm Resolution Systems, which enhance airport security checkpoints with advanced liquid explosive detection and adaptability to changing regulations (Product Related Announcements).Actualización del análisis • Oct 04
Global Healthcare Demand And PFAS Testing Will Drive Analytical Progress
Agilent Technologies received a modest analyst price target increase from $138.83 to $140.97. This reflects analysts' expectations for stable growth and slightly improved long-term valuation metrics.Actualización del análisis • Sep 16
Global Healthcare Demand And PFAS Testing Will Drive Analytical Progress
Agilent Technologies’ fair value estimates have remained stable, as reflected by marginal changes in both the consensus analyst price target (up slightly to $138.83) and the forward P/E (now 27.33x). What's in the News Raised full-year 2025 revenue guidance to $6.91–$6.93 billion, up 6.2–6.5% reported and 4.3–4.6% core, reflecting a $150 million increase at the midpoint and 1.5 points higher core growth.Artículo de análisis • Aug 03
Estimating The Intrinsic Value Of Agilent Technologies, Inc. (NYSE:A)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Agilent Technologies fair value estimate is US$114 With US$114...Artículo de análisis • Jul 01
What Is Agilent Technologies, Inc.'s (NYSE:A) Share Price Doing?
Today we're going to take a look at the well-established Agilent Technologies, Inc. ( NYSE:A ). The company's stock saw...Seeking Alpha • Apr 24
City Office REIT (RED PFD SER A): A High Yield, Deep Value Opportunity Worth Latching Onto
Summary City Office REIT's Series A Preferred Shares offer a tempting yield despite recent accounting losses and systemic pressures, suggesting a potential buying opportunity. The shares are cumulative, redeemable, and fixed, ensuring eventual dividend payments, though call risk and financial restructuring are potential concerns. The REIT's fundamentals, including an 85.8% occupancy rate and sector diversification, support sustainability, with positive economic profitability and AFFO figures. Despite macroeconomic risks, Series A's deep discount and commendable yield, along with manageable leverage ratios, led to us deeming it a 'Buy.' Read the full article on Seeking AlphaSeeking Alpha • Apr 07
Tariffs And Tactics: Agilent's Path Through Trade Disruption
Summary The April 2025 "Liberation Day" tariffs impose a 10% baseline tariff on all imports and additional surcharges, significantly impacting Agilent Technologies' cost structure and supply chain. Agilent's diversified global manufacturing footprint and strategic localization in China help mitigate some tariff impacts, but higher costs and competitive pressures remain concerns. Despite initial projections of modest financial impact, prolonged tariffs could necessitate further operational shifts, including relocating production and localizing R&D to maintain market access. Agilent's strong brand, advanced technology, and flexible supply chain position it to navigate tariff challenges, with potential long-term benefits from a more resilient global network. Read the full article on Seeking AlphaSeeking Alpha • Mar 01
Agilent Technologies: Recent Price Weakness Makes This Stock A Buy
Summary Agilent Technologies, a leader in life sciences and diagnostics, has a market cap of $38B and a 10-year CAGR of 13.6%. Key financial metrics: consistent revenue growth, stable gross profit margin above 50%, and a robust return on invested capital, despite some fluctuations. The stock fell too far after its recent earnings report, making it too good to pass up at its current level. Read the full article on Seeking AlphaPrevisiones de crecimiento de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
|---|---|---|---|---|---|
| 10/31/2028 | 8,377 | 1,909 | N/A | 2,189 | 11 |
| 10/31/2027 | 7,843 | 1,578 | 1,590 | 2,031 | 17 |
| 10/31/2026 | 7,393 | 1,487 | 1,116 | 1,641 | 16 |
| 1/31/2026 | 7,065 | 1,290 | 993 | 1,396 | N/A |
| 10/31/2025 | 6,948 | 1,303 | 1,152 | 1,559 | N/A |
| 7/31/2025 | 6,788 | 1,220 | 1,088 | 1,495 | N/A |
| 4/30/2025 | 6,628 | 1,166 | 1,189 | 1,585 | N/A |
| 1/31/2025 | 6,533 | 1,259 | 1,312 | 1,697 | N/A |
| 10/31/2024 | 6,510 | 1,289 | 1,373 | 1,751 | N/A |
| 7/31/2024 | 6,497 | 1,413 | 1,417 | 1,786 | N/A |
| 4/30/2024 | 6,591 | 1,242 | 1,538 | 1,896 | N/A |
| 1/31/2024 | 6,735 | 1,236 | 1,649 | 1,961 | N/A |
| 10/31/2023 | 6,833 | 1,240 | 1,474 | 1,772 | N/A |
| 7/31/2023 | 6,994 | 1,133 | 1,420 | 1,704 | N/A |
| 4/30/2023 | 7,040 | 1,351 | 1,183 | 1,468 | N/A |
| 1/31/2023 | 6,930 | 1,323 | 1,061 | 1,353 | N/A |
| 10/31/2022 | 6,848 | 1,254 | 1,021 | 1,312 | N/A |
| 7/31/2022 | 6,659 | 1,328 | 1,022 | 1,305 | N/A |
| 4/30/2022 | 6,527 | 1,263 | 1,058 | 1,313 | N/A |
| 1/31/2022 | 6,445 | 1,205 | 1,280 | 1,502 | N/A |
| 10/31/2021 | 6,319 | 1,210 | 1,297 | 1,485 | N/A |
| 7/31/2021 | 6,142 | 990 | 1,268 | 1,421 | N/A |
| 4/30/2021 | 5,817 | 925 | 1,253 | 1,377 | N/A |
| 1/31/2021 | 5,530 | 810 | 1,092 | 1,218 | N/A |
| 10/31/2020 | 5,339 | 719 | 802 | 921 | N/A |
| 7/31/2020 | 5,223 | 691 | 736 | 858 | N/A |
| 4/30/2020 | 5,236 | 683 | 665 | 810 | N/A |
| 1/31/2020 | 5,236 | 764 | 598 | 749 | N/A |
| 10/31/2019 | 5,163 | 1,071 | N/A | 1,021 | N/A |
| 7/31/2019 | 5,090 | 1,072 | N/A | 1,079 | N/A |
| 4/30/2019 | 5,019 | 1,117 | N/A | 1,034 | N/A |
| 1/31/2019 | 4,987 | 1,140 | N/A | 1,085 | N/A |
| 10/31/2018 | 4,914 | 316 | N/A | 1,087 | N/A |
| 7/31/2018 | 4,809 | 298 | N/A | 1,003 | N/A |
| 4/30/2018 | 4,720 | 237 | N/A | 1,034 | N/A |
| 1/31/2018 | 4,616 | 196 | N/A | 988 | N/A |
| 10/31/2017 | 4,472 | 684 | N/A | 889 | N/A |
| 7/31/2017 | 4,394 | 633 | N/A | 835 | N/A |
| 4/30/2017 | 4,324 | 582 | N/A | 801 | N/A |
| 1/31/2017 | 4,241 | 509 | N/A | 798 | N/A |
| 10/31/2016 | 4,202 | 462 | N/A | 793 | N/A |
| 7/31/2016 | 4,126 | 476 | N/A | 800 | N/A |
| 4/30/2016 | 4,096 | 465 | N/A | 714 | N/A |
| 1/31/2016 | 4,040 | 466 | N/A | 643 | N/A |
| 10/31/2015 | 4,038 | 438 | N/A | 1,322 | N/A |
| 7/31/2015 | 4,046 | 306 | N/A | 1,245 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (13.3% al año) de A es superior a la tasa de ahorro (3.5%).
Beneficios vs. Mercado: Se prevé que los beneficios (13.3% al año) de A crezcan menos que el mercado US (16.4% al año).
Beneficios de alto crecimiento: Se prevé que los beneficios de A crezcan, pero no significativamente.
Ingresos vs. Mercado: Se prevé que los ingresos (6.4% al año) de A crezcan más despacio que el mercado de US (11.4% al año).
Ingresos de alto crecimiento: Se prevé que los ingresos 6.4% al año) de A crezcan más despacio que 20% al año.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Se prevé que la rentabilidad financiera de A sea alta dentro de 3 años (21.7%)
Descubre empresas en crecimiento
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/05/07 13:00 |
| Precio de las acciones al final del día | 2026/05/07 00:00 |
| Beneficios | 2026/01/31 |
| Ingresos anuales | 2025/10/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Agilent Technologies, Inc. está cubierta por 34 analistas. 17 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Catherine Ramsey Schulte | Baird |
| Charles Butler | Barclays |
| Luke Sergott | Barclays |